Acupuncture is again shown to relieve migraine headaches

January 11, 2012

Acupuncture has been widely used for the treatment of migraine headaches and it has been subjected to many clinical trials. A new study published in the Canadian Medical Association Journal confirms what previous research has shown – that acupuncture in fact is effective. This study was performed by Chinese researchers and it involved 480 patients. It was a well-designed and rigorously conducted study. The doctors divided patients into 4 groups with 3 groups receiving different types of real acupuncture and the fourth one receiving sham acupuncture. Sham acupuncture group had needles inserted, but they were not manipulated to elicit a specific “qi” sensation, which was done in the real groups. Patients in all three groups receiving real acupuncture did better than those in the sham group. The benefit persisted for at least three months after the treatment. The difference was statistically significant (meaning it did not occur by chance) but not very large, mostly because the sham group also improved. In summary, this study strongly supports the results of previous clinical trials in migraines, which showed positive effects of acupuncture. It also showed that the type of acupuncture is not important, but needles need to be inserted properly and probably need to have electrical stimulation (all groups in this study had electrical stimulation). One difficulty in following the treatment used in this study is the need for doing acupuncture five days a week for 4 weeks. Many people may have difficulty finding the time (and money) for such a regimen. However, many of the previous positive studies were conducted with acupuncture treatment being performed once a week.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe